Epigenetic changes may explain chronic kidney disease

November 22, 2013

The research of physician-scientist Katalin Susztak, MD, PhD, associate professor of Medicine in the Renal Electrolyte and Hypertension Division, at the Perelman School of Medicine, University of Pennsylvania, strives to understand the molecular roots and genetic predisposition of chronic kidney disease. In a recent Genome Biology paper, Susztak, and her co-corresponding author John Greally from the Albert Einstein College of Medicine, Bronx, NY, found, in a genome-wide survey, significant differences in the pattern of chemical modifications on DNA that affect gene expression in kidney cells from patients with chronic kidney disease versus healthy controls. This is the first study to show that changes in these modifications – the cornerstone of the field of epigenetics – might explain chronic kidney disease.

Epigenetics is the science of how can be altered without actual changes in the DNA sequence. DNA can be modified by different chemical groups. In the case of this study, these are methyl groups that, like using sticky notes as reminders, open or close up regions of the genome to make these areas more or less available to be "read" as a gene.

Chronic kidney disease is a condition in which the kidneys are damaged and cannot adequately filter blood. This damage can cause wastes to build up, which leads to other health problems, including cardiovascular disease, anemia, and bone disease. More than 10% of people, or more than 20 million, aged 20 years or older in the United States have chronic kidney disease, according to the Centers for Disease Control.

Past epidemiological studies have shown that adverse intrauterine and postnatal conditions have a long-lasting, over-a-lifetime role in the development of chronic kidney disease. Adverse intrauterine factors include small size of babies for gestational age due to a lack of nutrients, or conversely, a large size for gestational age, for example if mom had pregnancy-related diabetes.

Studies from the Diabetes Control and Complications trial also indicate that patients with diabetes who had poor diabetes control 25 years earlier still have an increased risk of kidney disease despite having a decade of excellent glucose control. "This is called the metabolic memory effect," says Susztak. "Kidney cells remember the past bad metabolic environment."

Comparing Two Cell Types

Susztak's lab used human that looked almost the same under a microscope, but the way each cell type is affected by the methyl groups was very different. In general, an increase in the number of methyl groups on a gene turns off expression, and a decrease of methyl groups turns on a gene's expression.

Specifically, they found that the differences in the were not on promoter regions in the diseased kidney cells, but mostly on enhancer regions, and were also near sequences for important kidney transcription factors. "This all speaks to the importance of these regions in regulating ," says Susztak.

Promoter regions are in front of genes and near the gene they influence. Enhancer regions are farther away from the gene of influence. This difference indicates that the two cell types would likely respond differently to stress.

"The difference in methylation related to kidney fibrosis—genes encoding collagen and growth factors—at core kidney development sites in the genome raises the possibility that these differences are established early on in a person's development because the genes Pax2 and Pax8 are active in the developing kidney in the fetus," explains Susztak.

"Most of the research on kidney epigenetics so far has been on promoter regions on kidney cancer cells," says Susztak. "The difference we found in dysregulation between the two cell populations may indicate that dysregulation in cancer is different from dysregulation in chronic . Five years ago there was no epigenetic information outside of cancer," says Susztak.

Overall, the findings raise the possibility that dysregulation of epigenetic marks plays a role in by affecting pathways that lead to more fibrosis. Identifying the genes and proteins associated with this system gone awry may help identify new biomarkers and targets for new drugs.

Explore further: ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

Related Stories

ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

November 11, 2013
(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published ...

Obesity suppresses cellular process critical to kidney health

October 5, 2013
Obesity increases a chronic kidney disease patient's risk of developing kidney failure.

Sex differences in kidney gene expression

July 31, 2013
Male and female rats show different patterns of kidney gene expression throughout their lives, a study in the open access journal Biology of Sex Differences reveals. The finding could help explain some of the gender differences ...

Kidney disease in Canada: 12.5 percent of adults afflicted, yet many unaware

May 6, 2013
An estimated 12.5% of Canadians in Canada have evidence of chronic kidney disease, including people without risk factors such as high blood pressure and diabetes, according to a study published in CMAJ.

Researchers looking at new way to treat chronic kidney disease and heart failure

October 16, 2013
Researchers at St. Michael's Hospital are using adult bone marrow stem cells as they investigate a completely new way of treating chronic kidney disease and heart failure in rats.

Moderate to severe psoriasis linked to chronic kidney disease, say experts

October 15, 2013
Moderate to severe psoriasis is associated with an increased risk of chronic kidney disease independent of traditional risk factors, such as diabetes and heart disease, finds a study published in BMJ today.

Recommended for you

Gene variant activity is surprisingly variable between tissues

August 21, 2017
Every gene in almost every cell of the body is present in two variants called alleles—one from the mother, the other one from the father. In most cases, both alleles are active and transcribed by the cells into RNA. However, ...

Genome analysis with near-complete privacy possible, say researchers

August 17, 2017
It is now possible to scour complete human genomes for the presence of disease-associated genes without revealing any genetic information not directly associated with the inquiry, say Stanford University researchers.

Science Says: DNA test results may not change health habits

August 17, 2017
If you learned your DNA made you more susceptible to getting a disease, wouldn't you work to stay healthy?

Genetic variants found to play key role in human immune system

August 16, 2017
It is widely recognized that people respond differently to infections. This can partially be explained by genetics, shows a new study published today in Nature Communications by an international collaboration of researchers ...

Active non-coding DNA might help pinpoint genetic risk for psychiatric disorders

August 16, 2017
Northwestern Medicine scientists have demonstrated a new method of analyzing non-coding regions of DNA in neurons, which may help to pinpoint which genetic variants are most important to the development of schizophrenia and ...

Phenotype varies for presumed pathogenic variants in KCNB1

August 16, 2017
(HealthDay)—De novo KCNB1 missense and loss-of-function variants are associated with neurodevelopmental disorders, with or without seizures, according to a study published online Aug. 14 in JAMA Neurology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.